LEveraging Insights on the Clinical Relevance of GliclAzide for GluCo-Centric & BeYond Benefits in T2DM Care Continuum: An Indian KAP Study (LEGACY-INDIA)

This prospective, observational, KAP survey will begin after Ethics Committee (IEC) approval. Approximately, 250 healthcare professionals will be randomly invited to participate and will provide written informed consent. A 20 to 25 item quesstionnaire, validated by expert clinicians, will be administered via Google Forms, paper format, or interviews. Responses will be analyzed to assess clinicians’ knowledge, attitudes, and practices regarding the clinical relevance of gliclazide in glucose control and microvascular complications. The survey will take up to 1.5 hours, and all data will remain confidential and anonymized